Literature DB >> 28349188

[Erectile dysfunction : Current diagnostics and treatment].

C Leiber1.   

Abstract

Erectile dysfunction is a medical disease with extensive influence on the quality of life and well-being of patients and their female or male partners. Nowadays, most of the underlying pathological factors are well known. The general medical history with the question of possible risk factors and the specific sexual history play the most important roles in the guideline-based diagnostics. In addition, a thorough clinical examination and specific laboratory tests should be carried out. Phosphodiesterase 5 (PDE-5) inhibitors, vacuum devices, injection therapy and penile prostheses are the options for an evidence-based and individual treatment of affected patients. The success rates are high in most cases. Every urologist, andrologist and practitioner of sexual medicine should have detailed knowledge in this field.

Entities:  

Keywords:  Cardiovascular risk factors; Erectile dysfunction; Injection therapy; Penile prosthesis; Phosphodiesterase 5 inhibitors

Mesh:

Substances:

Year:  2017        PMID: 28349188     DOI: 10.1007/s00120-017-0355-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  13 in total

1.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Authors:  I Goldstein; T F Lue; H Padma-Nathan; R C Rosen; W D Steers; P A Wicker
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

2.  The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

Authors:  R C Rosen; A Riley; G Wagner; I H Osterloh; J Kirkpatrick; A Mishra
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

Review 3.  Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.

Authors:  Liang Chen; Sergej E L Staubli; Marc P Schneider; Alfons G Kessels; Sandra Ivic; Lucas M Bachmann; Thomas M Kessler
Journal:  Eur Urol       Date:  2015-03-26       Impact factor: 20.096

4.  Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.

Authors:  M Braun; G Wassmer; T Klotz; B Reifenrath; M Mathers; U Engelmann
Journal:  Int J Impot Res       Date:  2000-12       Impact factor: 2.896

Review 5.  First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis.

Authors:  G Corona; G Rastrelli; A Burri; E Serra; D Gianfrilli; E Mannucci; E A Jannini; M Maggi
Journal:  Andrology       Date:  2016-09-16       Impact factor: 3.842

6.  Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation.

Authors:  Konstantinos Hatzimouratidis; Edouard Amar; Ian Eardley; Francois Giuliano; Dimitrios Hatzichristou; Francesco Montorsi; Yoram Vardi; Eric Wespes
Journal:  Eur Urol       Date:  2010-02-20       Impact factor: 20.096

Review 7.  The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine.

Authors:  Graham Jackson; Raymond C Rosen; Robert A Kloner; John B Kostis
Journal:  J Sex Med       Date:  2006-01       Impact factor: 3.802

Review 8.  Implants, mechanical devices, and vascular surgery for erectile dysfunction.

Authors:  Wayne J G Hellstrom; Drogo K Montague; Ignacio Moncada; Culley Carson; Suks Minhas; Geraldo Faria; Sudhakar Krishnamurti
Journal:  J Sex Med       Date:  2010-01       Impact factor: 3.802

9.  Erectile function in men with diabetes type 2: correlation with glycemic control.

Authors:  H Awad; A Salem; A Gadalla; N Abou El Wafa; O A Mohamed
Journal:  Int J Impot Res       Date:  2009-09-17       Impact factor: 2.896

10.  Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.

Authors:  Gerald B Brock; Chris G McMahon; K K Chen; Timothy Costigan; Wei Shen; Vish Watkins; Greg Anglin; Steve Whitaker
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.